Aphelion Capital

Aphelion Capital is a healthcare venture capital firm dedicated to investing in capital-efficient products and services that enhance patient outcomes while lowering costs within the healthcare system. The firm focuses on early and mid-stage medical device and digital health companies, partnering with passionate leaders committed to addressing current healthcare challenges. Aphelion Capital has established strategic relationships to provide its portfolio companies with essential resources for success in the healthcare ecosystem.

The firm's investment strategy emphasizes innovation, seeking medical technologies and services that offer novel approaches to healthcare delivery. Aphelion Capital values exceptional teams, whether first-time entrepreneurs or experienced startup CEOs, who are united by a shared vision for their technology. The firm also prioritizes economic considerations, investing in ideas and technologies that deliver better outcomes at the same or lower cost to the healthcare system. Additionally, Aphelion Capital offers collaborative capital, providing meaningful support to portfolio companies through an extensive network and active strategic limited partners.

Founded in 2005, Aphelion Capital has made 39 investments, with its most recent on March 19, 2025, in Biolinq. The firm has raised five funds, including the latest, Aphelion Cardeation II, announced on July 18, 2022. Notable exits include Phagenesis, ExplORer Surgical, and Bardy Diagnostics. The firm's portfolio includes companies such as Aurora SFC Systems Inc., Broncus Technologies Inc., Foxhollow Technologies Inc., InSound Medical Inc., and OrthoScan Inc., reflecting its commitment to advancing medical technology and improving healthcare delivery.